Bausch Health Companies Inc.

NYSE:BHC Stock Report

Market Cap: US$2.8b

Bausch Health Companies Management

Management criteria checks 2/4

Bausch Health Companies' CEO is Tom Appio, appointed in May 2022, has a tenure of 2.17 years. total yearly compensation is $15.88M, comprised of 7.4% salary and 92.6% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $3.17M. The average tenure of the management team and the board of directors is 2.3 years and 8 years respectively.

Key information

Tom Appio

Chief executive officer

US$15.9m

Total compensation

CEO salary percentage7.4%
CEO tenure2.2yrs
CEO ownership0.1%
Management average tenure2.3yrs
Board average tenure8yrs

Recent management updates

Recent updates

The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

May 21
The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results

May 07

Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation

Feb 24

Bausch Health: $20bn Debt Is A Mighty Elephant In The Room

Nov 30

Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?

Nov 01
Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?

Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics

Sep 24

Is Bausch Health Companies (NYSE:BHC) A Risky Investment?

Jul 24
Is Bausch Health Companies (NYSE:BHC) A Risky Investment?

Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes

Jul 06

What To Do After Bausch Health Stock Plunged By Nearly 9% Again

Jun 07

Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt

Apr 18
Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt

Bausch Health: A Basket Case Of A Business Only A Hedge Fund Can Bail Out

Dec 30

Bausch Health acne lotion Arazlo available in Canada under public drug plans

Dec 22

Bausch Health: Things To Consider Before Investing

Dec 11

Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues

Nov 10
Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues

Bausch Health Companies Q3 2022 Earnings Preview

Nov 02

Bausch Health: Long-Term Need To Place Stops For Protection

Sep 28

Bausch Health Companies: Equity Stub Would Benefit From Ambitious Spinoff

Sep 21

Bausch Health sheds 10% as FDA grants tentative approval for Xifaxan generic

Sep 08

Bausch Health begin offers to exchange debt up to $4B

Aug 31

CEO Compensation Analysis

How has Tom Appio's remuneration changed compared to Bausch Health Companies's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$455m

Dec 31 2023US$16mUS$1m

-US$592m

Sep 30 2023n/an/a

-US$963m

Jun 30 2023n/an/a

-US$186m

Mar 31 2023n/an/a

-US$357m

Dec 31 2022US$13mUS$1m

-US$225m

Sep 30 2022n/an/a

US$254m

Jun 30 2022n/an/a

US$43m

Mar 31 2022n/an/a

-US$407m

Dec 31 2021US$10mUS$854k

-US$948m

Sep 30 2021n/an/a

-US$1b

Jun 30 2021n/an/a

-US$1b

Mar 31 2021n/an/a

-US$1b

Dec 31 2020US$4mUS$775k

-US$560m

Sep 30 2020n/an/a

-US$2b

Jun 30 2020n/an/a

-US$2b

Mar 31 2020n/an/a

-US$2b

Dec 31 2019US$4mUS$769k

-US$2b

Sep 30 2019n/an/a

-US$616m

Jun 30 2019n/an/a

-US$917m

Mar 31 2019n/an/a

-US$2b

Dec 31 2018US$4mUS$730k

-US$4b

Sep 30 2018n/an/a

-US$3b

Jun 30 2018n/an/a

-US$2b

Mar 31 2018n/an/a

-US$805m

Dec 31 2017US$3mUS$650k

US$2b

Compensation vs Market: Tom's total compensation ($USD15.88M) is above average for companies of similar size in the US market ($USD6.74M).

Compensation vs Earnings: Tom's compensation has increased whilst the company is unprofitable.


CEO

Tom Appio (62 yo)

2.2yrs

Tenure

US$15,878,578

Compensation

Mr. Thomas J. Appio, also known as Tom, serves as the Chief Executive Officer & Director at Bausch Health Companies Inc. and served as Chief Executive Officer of Pharma Business and served as President & C...


Leadership Team

NamePositionTenureCompensationOwnership
Thomas Appio
CEO & Director2.2yrsUS$15.88m0.11%
$ 3.2m
John Barresi
Senior VP2.1yrsUS$1.40m0.0055%
$ 153.1k
Seana Carson
Executive VP & General Counsel2.2yrsUS$3.16m0.023%
$ 625.0k
Mirza Dautbegovic
Executive VP & COO2.5yrsno data0.024%
$ 674.1k
Kathleen Fitzpatrick
Executive VP and Chief HR & Communications Officer2.5yrsno datano data
Josh Coyle
Senior Vice President of Sales & Salix1.5yrsno datano data
Tage Ramakrishna
Chief Medical Officer and President of R&Dno datano datano data
Jeff Hartness
Executive VP of Market Access4.1yrsno datano data
Graham Jackson
Senior VP & Chief Quality Officer2.5yrsno datano data
Cees Heiman
Senior Vice President of Europe & Canada2.5yrsno datano data
Donald Pearl
Senior Vice President of Ortho Dermatologicsno datano datano data
Jiny Kim
Senior Vice President of Solta Medical1.5yrsno datano data

2.3yrs

Average Tenure

51yo

Average Age

Experienced Management: BHC's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Thomas Appio
CEO & Director2.2yrsUS$15.88m0.11%
$ 3.2m
John Paulson
Independent Chairman2.1yrsUS$812.50k0.000060%
$ 1.7k
Robert Power
Independent Director15.9yrsUS$389.55k0.0018%
$ 49.8k
H. Fibiger
Chairman of External Advisory Boardno dataUS$2.00mno data
Sarah Kavanagh
Independent Director8yrsUS$718.28k0%
$ 0
Robert Lenox
Member of the External Advisory Board15.3yrsno datano data
Kathleen Clarence-Smith
Member of the External Advisory Board15.3yrsno datano data
Karoly Nikolich
Member of the External Advisory Board15.3yrsno datano data
Brett Icahn
Independent Director3.3yrsUS$691.72k0.00020%
$ 5.5k
Amy Wechsler
Independent Director8.1yrsUS$377.50k0.011%
$ 318.2k
Steven Miller
Independent Director3.3yrsUS$381.31k0.031%
$ 852.1k
Christian Garcia
Independent Directorless than a yearno datano data

8.0yrs

Average Tenure

67yo

Average Age

Experienced Board: BHC's board of directors are considered experienced (8 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.